tpm502
Peptideexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 12, 2022 (NCT05660109)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05660109 | Phase 2 | Dec 12, 2022 | Topas Therapeutics GmbH, University of Oslo |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Topas Therapeutics GmbH | For profit | 1 | 1 | 1 | 2022 |
| University of Oslo | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1